id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-1575-0005,FDA,FDA-2013-E-1575,"Determination of Regulatory Review Period for Purposes of Patent
Extension; RAXIBACUMAB",Notice,Determinations,2015-12-15T05:00:00Z,2015,12,2015-12-15T05:00:00Z,2016-02-17T04:59:59Z,2015-12-15T16:00:10Z,2015-31400,0,0,0900006481da7506
FDA-2013-E-1575-0004,FDA,FDA-2013-E-1575,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2015-11-18T05:00:00Z,2015,11,2015-11-18T05:00:00Z,,2015-11-18T14:36:12Z,,0,0,0900006481d50289